Terazosin hydrochloride dihydrate is the hydrochloride salt dihydrate form of terazosin, a quinazoline derivative that selectively blocks alpha-1 adrenergic receptors, leading to vasodilation and reduced peripheral vascular resistance. It is primarily supplied as an active pharmaceutical ingredient for use in manufacturing finished dosage forms.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 70024-40-7
Terazosin hydrochloride
pharmaceutical raw material
Terazosin
pharmaceutical raw material
Imidazole-1-propanol, 2-methyl-5-nitro-, hydrochloride
pharmaceutical raw material
Cimetidine hydrochloride
pharmaceutical raw material
Galunisertib
pharmaceutical raw material
Tranexamic acid
pharmaceutical raw material
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone;dihydrate;hydrochloride
NZMOFYDMGFQZLS-UHFFFAOYSA-N
COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC.O.O.Cl